MedTrace Logo

the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin

NCT05494320 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-08-09

No results posted yet for this study

Summary

Study the effect of genetic polymorphism (rs1885301, rs4148396 and rs3740066) in the membrane of Multidrug resistance protein 2 (MRP2) encoded by ATP-binding cassette C2 (ABCC2) gene and its genetic expression levels on neurotoxicity in gasrtointestinal cancer patients reciving Oxaliplatin-based chemotherapy.

Conditions

Interventions

DRUG

Folfox Protocol

Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nagwa Ali Sabri, Professor · Clinical Pharmacy Department - Faculty of Pharmacy - Ain Shams University

  • May Ahmed Shawki, Lecturer · Clinical Pharmacy Department - Faculty of Pharmacy - Ain Shams University

  • Diaa Eldin Moussa Sherif, Lecturer · Clinical oncology and nuclear medicine Department -Faculty of medicine-Ain Shams University

  • Sara Mohamed Abdel Aziz, Master Student · Clinical Pharmacy Department - Faculty of Pharmacy - Ain Shams University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-15
Primary Completion
2022-08-05
Completion
2022-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494320 on ClinicalTrials.gov